Emerging Nanotechnology in Chronic Respiratory Diseases

Parijat Pandey; Meenu Mehta; Shakti Shukla; Ridhima Wadhwa; Gautam Singhvi; Dinesh Kumar Chellappan; Saurabh Satija; Gaurav Gupta; Rajendra Awasthi; Parteek Prasher; Philip M. Hansbro; Kamal Dua; Harish Dureja

doi:10.1007/978-3-030-41858-8_20

Emerging Nanotechnology in Chronic Respiratory Diseases

Parijat Pandey
, Meenu Mehta
, Shakti Shukla
, Ridhima Wadhwa
, Gautam Singhvi
, Dinesh Kumar Chellappan
, Saurabh Satija
, Gaurav Gupta
, Rajendra Awasthi
, Parteek Prasher
, Philip M. Hansbro
, Kamal Dua
, Harish Dureja

Shri Baba Mastnath Institute of Pharmaceutical Sciences and Research
Royal Prince Alfred Hospital
University of Technology Sydney
University of Newcastle
South Asian University
Birla Institute of Technology and Science Pilani
International Medical University
Lovely Professional University
Suresh Gyan Vihar University
Amity University, Noida
University of Petroleum and Energy Studies
Shoolini University of Biotechnology and Management Sciences
Maharshi Dayanand University

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

11 Scopus citations

Abstract

A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.

Original language	English
Title of host publication	Nanoformulations in Human Health
Subtitle of host publication	Challenges and Approaches
Publisher	Springer International Publishing
Pages	449-468
Number of pages	20
ISBN (Electronic)	9783030418588
ISBN (Print)	9783030418571
DOIs	https://doi.org/10.1007/978-3-030-41858-8_20
State	Published - 1 Jan 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Asthma
Chronic respiratory disease
Dendrimers
Liposomes
Nanotechnology

Access to Document

10.1007/978-3-030-41858-8_20

Cite this

Pandey, P., Mehta, M., Shukla, S., Wadhwa, R., Singhvi, G., Chellappan, D. K., Satija, S., Gupta, G., Awasthi, R., Prasher, P., Hansbro, P. M., Dua, K., & Dureja, H. (2020). Emerging Nanotechnology in Chronic Respiratory Diseases. In Nanoformulations in Human Health: Challenges and Approaches (pp. 449-468). Springer International Publishing. https://doi.org/10.1007/978-3-030-41858-8_20

@inbook{0fb9164c992b4b88a1a297fd78e739d4,

title = "Emerging Nanotechnology in Chronic Respiratory Diseases",

abstract = "A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.",

keywords = "Asthma, Chronic respiratory disease, Dendrimers, Liposomes, Nanotechnology",

author = "Parijat Pandey and Meenu Mehta and Shakti Shukla and Ridhima Wadhwa and Gautam Singhvi and Chellappan, \{Dinesh Kumar\} and Saurabh Satija and Gaurav Gupta and Rajendra Awasthi and Parteek Prasher and Hansbro, \{Philip M.\} and Kamal Dua and Harish Dureja",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-3-030-41858-8\_20",

language = "English",

isbn = "9783030418571",

pages = "449--468",

booktitle = "Nanoformulations in Human Health",

publisher = "Springer International Publishing",

address = "Switzerland",

}

TY - CHAP

T1 - Emerging Nanotechnology in Chronic Respiratory Diseases

AU - Pandey, Parijat

AU - Mehta, Meenu

AU - Shukla, Shakti

AU - Wadhwa, Ridhima

AU - Singhvi, Gautam

AU - Chellappan, Dinesh Kumar

AU - Satija, Saurabh

AU - Gupta, Gaurav

AU - Awasthi, Rajendra

AU - Prasher, Parteek

AU - Hansbro, Philip M.

AU - Dua, Kamal

AU - Dureja, Harish

PY - 2020/1/1

Y1 - 2020/1/1

N2 - A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.

AB - A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.

KW - Asthma

KW - Chronic respiratory disease

KW - Dendrimers

KW - Liposomes

KW - Nanotechnology

UR - https://www.scopus.com/pages/publications/85092459190

U2 - 10.1007/978-3-030-41858-8_20

DO - 10.1007/978-3-030-41858-8_20

M3 - Chapter

AN - SCOPUS:85092459190

SN - 9783030418571

SP - 449

EP - 468

BT - Nanoformulations in Human Health

PB - Springer International Publishing

ER -

Emerging Nanotechnology in Chronic Respiratory Diseases

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this